These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36780200)

  • 1. Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
    Anderson P; Ghisoli M; Crompton BD; Klega KS; Wexler LH; Slotkin EK; Stanbery L; Manning L; Wallraven G; Manley M; Horvath S; Bognar E; Nemunaitis J
    Clin Cancer Res; 2023 May; 29(9):1689-1697. PubMed ID: 36780200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.
    Palmerini E; Jones RL; Setola E; Picci P; Marchesi E; Luksch R; Grignani G; Cesari M; Longhi A; Abate ME; Paioli A; Szucs Z; D'ambrosio L; Scotlandi K; Fagioli F; Asaftei S; Ferrari S
    Acta Oncol; 2018 Jul; 57(7):958-964. PubMed ID: 29533113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
    Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
    Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.
    Ghisoli M; Barve M; Mennel R; Lenarsky C; Horvath S; Wallraven G; Pappen BO; Whiting S; Rao D; Senzer N; Nemunaitis J
    Mol Ther; 2016 Aug; 24(8):1478-83. PubMed ID: 27109631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
    Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
    BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
    Chugh R; Ballman KV; Helman LJ; Patel S; Whelan JS; Widemann B; Lu Y; Hawkins DS; Mascarenhas L; Glod JW; Ji J; Zhang Y; Reinke D; Strauss SJ
    Cancer; 2021 Apr; 127(8):1301-1310. PubMed ID: 33289920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
    Salah S; To YH; Khozouz O; Ismail T; Yaser S; Alnsour A; Shahin O; Sultan I; Abuhijlih R; Halalsheh H; Abuhijla F; Lewin J
    Clin Transl Oncol; 2021 Apr; 23(4):757-763. PubMed ID: 32761317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
    Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
    Xu J; Xie L; Sun X; Liu K; Liang X; Cai Z; Tang X; Guo W
    Clin Cancer Res; 2023 Mar; 29(6):1040-1046. PubMed ID: 36622702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
    Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
    Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
    Ju HY; Park M; Lee JA; Park HJ; Park SY; Kim JH; Kang HG; Yang HC; Park BK
    Cancer Res Treat; 2022 Apr; 54(2):563-571. PubMed ID: 34126703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
    Raciborska A; Bilska K; Drabko K; Chaber R; Pogorzala M; Wyrobek E; Polczyńska K; Rogowska E; Rodriguez-Galindo C; Wozniak W
    Pediatr Blood Cancer; 2013 Oct; 60(10):1621-5. PubMed ID: 23776128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from
    Schmidkonz C; Krumbholz M; Atzinger A; Cordes M; Goetz TI; Prante O; Ritt P; Schaefer C; Agaimy A; Hartmann W; Rössig C; Fröhlich B; Bäuerle T; Dirksen U; Kuwert T; Metzler M
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1564-1575. PubMed ID: 31853559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
    Wang BC; Xiao BY; Lin GH
    BMC Cancer; 2022 Mar; 22(1):349. PubMed ID: 35361149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
    Casey DA; Wexler LH; Merchant MS; Chou AJ; Merola PR; Price AP; Meyers PA
    Pediatr Blood Cancer; 2009 Dec; 53(6):1029-34. PubMed ID: 19637327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
    Wagner LM; McAllister N; Goldsby RE; Rausen AR; McNall-Knapp RY; McCarville MB; Albritton K
    Pediatr Blood Cancer; 2007 Feb; 48(2):132-9. PubMed ID: 16317751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
    Subbiah V; Braña I; Longhi A; Boni V; Delord JP; Awada A; Boudou-Rouquette P; Sarantopoulos J; Shapiro GI; Elias A; Ratan R; Fernandez C; Kahatt C; Cullell-Young M; Siguero M; Zeaiter A; Chawla SP
    Clin Cancer Res; 2022 Jul; 28(13):2762-2770. PubMed ID: 35486638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
    Rocconi RP; Stevens EE; Bottsford-Miller JN; Ghamande SA; Elder J; DeMars LL; Munkarah A; Aaron P; Stanbery L; Wallraven G; Bognar E; Manley M; Horvath S; Manning L; Walter A; Galanis E; Herzog T; Monk BJ; Coleman RL; Nemunaitis J
    Cancer Gene Ther; 2022 Mar; 29(3-4):369-382. PubMed ID: 33753870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.
    Federico SM; Pappo AS; Sahr N; Sykes A; Campagne O; Stewart CF; Clay MR; Bahrami A; McCarville MB; Kaste SC; Santana VM; Helmig S; Gartrell J; Shelat A; Brennan RC; Hawkins D; Godwin K; Bishop MW; Furman WL; Stewart E
    Eur J Cancer; 2020 Sep; 137():204-213. PubMed ID: 32795876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.